Enzymatica recruits Chief Operating Officer
July 14 2017 - 5:30AM
Press release
Lund, 14 July, 2017
Enzymatica recruits Chief
Operating Officer
Enzymatica has recruited Johan
Lindvall as Chief Operating Officer and Executive Vice President.
He will be responsible for Enzymatica's production, logistics and
product development. He has many years of experience in
international and Swedish companies in medical devices and high
tech.
"There are exciting opportunities for Enzymatica
with its patented barrier technology on which the common cold spray
ColdZyme® is based. I look forward to being able to
contribute with my operational experience in a demanding medical
device sector, and in the global market. My goal is to contribute
to Enzymatica becoming a respected business partner with an
interesting product portfolio," says Johan.
"We are very pleased to have recruited Johan who, with his
experience, will play a key role in enabling us to cope with the
production volumes and the demands from our international
distributors for efficient production and logistics, and in taking
responsibility for continued product development," says Fredrik
Lindberg, CEO of Enzymatica.
One of Johan Lindvall's previous positions was as
Supply Chain Director for the Nordic countries in Biomet, with
responsibility for logistics and customer service. Biomet, now
Zimmer Biomet, is a world-leading orthopaedic company. Johan
Lindvall has also been Plant Director and had assignments in
European operations for Biomet. He joins Enzymatica from a position
as Deputy CEO and Chief Operating Office of Agellis Group, which
develops, manufactures and markets measuring instruments and
monitoring equipment for the global metal industry. Johan Lindvall
has previously held senior positions in supply chain and product
development in companies such as Volvo Excavators AB and Precise
Biometrics AB.
For
more information, contact:
Fredrik Lindberg, CEO of Enzymatica AB
Tel: +46 (0)708-86 53 70, e-mail
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica AB is a medical device company that develops and sells
medical devices for infection-related diseases. In a short period
of time, the company has developed ColdZyme®, a unique mouth spray
for the common cold, has launched the product in eight markets and
has established it among the top-selling cold products in Swedish
kronor terms at Swedish pharmacies. The strategy is to continue to
grow by strengthening the company's position in existing markets
and expanding into new geographical markets through established
partners. The company is headquartered in Lund and is listed on
Nasdaq First North. For more information,
visit: www.enzymatica.se.
Enzymatica's Certified Adviser is Erik Penser Bank.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Sep 2024 to Oct 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Oct 2023 to Oct 2024